Meeder Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Meeder Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8	Closed	-$1K	–	2051
2022 Q3	$1K	Hold	8	–	–	﹤0.01%	2038
2022 Q2	$1K	Sell	8 -11	-58%	-$826	﹤0.01%	2098
2022 Q1	$2K	Hold	19	–	–	﹤0.01%	2094
2021 Q4	$2K	Buy	19 +8	+73%	+$965	﹤0.01%	1002
2021 Q3	$1K	Sell	11 -8	-42%	-$1.03K	﹤0.01%	2389
2021 Q2	$3K	Hold	19	–	–	﹤0.01%	2139
2021 Q1	$3K	Hold	19	–	–	﹤0.01%	2013
2020 Q4	$3K	Buy	19 +10	+111%	+$1.28K	﹤0.01%	1408
2020 Q3	$1K	Buy	+9	New	+$1.01K	﹤0.01%	2068
2020 Q2	–	Sell	-5	Closed	–	–	2514
2020 Q1	$0	Sell	5 -41	-89%	-$3.63K	﹤0.01%	2563
2019 Q4	$4K	Buy	46 +26	+130%	+$2.25K	﹤0.01%	1868
2019 Q3	$2K	Buy	+20	New	+$1.66K	﹤0.01%	1998

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Meeder Asset Management's XBI Position: Q4 2022 in Review

Meeder Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 8 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in XBI in Q3 2019 and held it in 12 quarters. The position peaked at $4K in Q4 2019. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Meeder Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 8 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $1K.
Meeder Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2019 and held it in 12 quarters.
Meeder Asset Management's State Street SPDR S&P Biotech ETF position peaked at $4K in Q4 2019.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.